I took a look at the the deruxtecan part of the Enhertu drug combination which is where the worst side effects lie due to cytotoxicity.. I decided to take a quick look at the active side, trastuzumab. Trastuzumab's mechanism of action stops the downstream effects of the HER2 receptor.

Those downstream effects (Ras/Raf, PI3K/Akt, PLCy and PKC) are very familiar because they are all downregulated by leronlimab. It would seem that leronlimab would also do very well in HER2 positive cancers.